Free Trial

Inventiva (IVA) Competitors

Inventiva logo
$3.70 -0.06 (-1.60%)
As of 04/30/2025 01:09 PM Eastern

IVA vs. XNCR, AVXL, ABCL, DAWN, CVAC, QURE, PRAX, IMNM, BCAX, and REPL

Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Xencor (XNCR), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), Day One Biopharmaceuticals (DAWN), CureVac (CVAC), uniQure (QURE), Praxis Precision Medicines (PRAX), Immunome (IMNM), Bicara Therapeutics (BCAX), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

Inventiva vs.

Xencor (NASDAQ:XNCR) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.

Xencor has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Inventiva has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Inventiva's return on equity of 0.00% beat Xencor's return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-232.77% -30.92% -21.74%
Inventiva N/A N/A N/A

19.1% of Inventiva shares are owned by institutional investors. 5.2% of Xencor shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xencor received 485 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 73.24% of users gave Xencor an outperform vote.

CompanyUnderperformOutperform
XencorOutperform Votes
509
73.24%
Underperform Votes
186
26.76%
InventivaOutperform Votes
24
82.76%
Underperform Votes
5
17.24%

Inventiva has lower revenue, but higher earnings than Xencor.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$110.49M7.10-$126.09M-$3.51-3.14
Inventiva$9.20M21.11-$119.51MN/AN/A

In the previous week, Xencor had 5 more articles in the media than Inventiva. MarketBeat recorded 10 mentions for Xencor and 5 mentions for Inventiva. Xencor's average media sentiment score of 1.15 beat Inventiva's score of 0.66 indicating that Xencor is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inventiva
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xencor currently has a consensus price target of $32.86, indicating a potential upside of 198.16%. Inventiva has a consensus price target of $10.40, indicating a potential upside of 181.08%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Inventiva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Inventiva
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

Xencor beats Inventiva on 9 of the 17 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVA vs. The Competition

MetricInventivaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$194.17M$6.89B$5.57B$7.82B
Dividend YieldN/A3.06%5.11%4.22%
P/E RatioN/A7.4422.4418.48
Price / Sales21.11242.66394.66103.91
Price / CashN/A65.8538.1834.62
Price / Book-5.526.516.774.25
Net Income-$119.51M$143.21M$3.22B$248.23M
7 Day Performance-3.65%3.97%3.09%3.29%
1 Month Performance26.24%0.37%-0.14%2.43%
1 Year Performance17.09%2.59%17.98%5.54%

Inventiva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IVA
Inventiva
1.9363 of 5 stars
$3.70
-1.6%
$10.40
+181.1%
+17.1%$194.17M$9.20M0.00100Gap Down
XNCR
Xencor
3.24 of 5 stars
$10.60
+9.3%
$33.86
+219.4%
-47.4%$746.90M$110.49M-3.31280Upcoming Earnings
Analyst Forecast
Positive News
AVXL
Anavex Life Sciences
3.8167 of 5 stars
$8.76
-2.1%
$44.00
+402.3%
+160.3%$745.16MN/A-15.9340Upcoming Earnings
Positive News
Gap Down
ABCL
AbCellera Biologics
2.5888 of 5 stars
$2.45
+1.2%
$7.50
+206.1%
-31.0%$730.07M$28.83M-4.02500Upcoming Earnings
Gap Down
DAWN
Day One Biopharmaceuticals
2.4717 of 5 stars
$7.14
+4.4%
$32.29
+352.2%
-54.5%$723.67M$131.16M-6.9360Upcoming Earnings
CVAC
CureVac
4.1276 of 5 stars
$3.21
+2.9%
$10.00
+211.5%
+40.9%$720.13M$535.18M5.84880Analyst Forecast
Positive News
QURE
uniQure
2.4031 of 5 stars
$13.29
+2.2%
$38.80
+191.9%
+234.7%$718.68M$27.12M-2.68500Upcoming Earnings
Short Interest ↑
Gap Down
High Trading Volume
PRAX
Praxis Precision Medicines
3.4744 of 5 stars
$35.34
+4.6%
$123.33
+249.0%
-31.4%$712.56M$8.55M-3.43110Positive News
IMNM
Immunome
2.5927 of 5 stars
$8.00
+1.1%
$25.14
+214.3%
-37.5%$695.61M$9.04M-0.9940Positive News
Gap Down
BCAX
Bicara Therapeutics
N/A$12.65
+4.0%
$32.43
+156.4%
N/A$689.72MN/A0.0032Analyst Revision
News Coverage
Positive News
Gap Down
REPL
Replimune Group
4.1827 of 5 stars
$8.77
+9.8%
$19.43
+121.5%
+54.0%$675.42MN/A-2.86210Positive News

Related Companies and Tools


This page (NASDAQ:IVA) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners